CEO Doug Biehn sits down with Nasdaq’s Leigh Hixon to share Octave’s vision of transforming neurodegenerative disease care through precision medicine. Watch Now

Octave at the ACTRIMS 2025 Annual Meeting

February 27 – March 1, 2025
West Palm Beach, Florida

Schedule time with the Octave team

We'd love to meet you at ACTRIMS!

  • Are you interested in learning more about the Octave MSDA Test?
  • Are you an existing user wanting to review specific cases with our MSL team?
  • Are you curious to discuss future partnership opportunities?
Our pod hours:
  • Thursday, February 27: 7:30 AM – 7:30 PM
  • Friday, February 28: 7:30 AM – 7:30 PM
MSDA Test Use Cases

Discover how the MSDA Test is used in real-world clinics to impact treatment decision making

The science behind our innovation

Engage with our researchers and collaborators at Poster Session 1 (Feb. 27, 6PM - 7:30PM)

P048: MSDA Test Reveals Distinct Disease Activity Trajectories for Ublituximab and Teriflunomide in ULTIMATE I and II Trials

P147: Two-Year Findings on the Safety and Efficacy of Cladribine Tablets after Treatment with Natalizumab (CLADRINA Trial)

P029: Real-world Clinical Utility of a Multi-protein, Blood-based Biomarker Assay for Disease Activity Assessments in Multiple Sclerosis

P061: Serum-Based Proteomic Characteristics of Severely-Affected Multiple Sclerosis

Octave @ ACTRIMS

Our team is excited to meet with you at ACTRIMS!

Resources

Help your patients and network gain a better understanding of how Octave can improve MS care management

A helpful guide of what our MSDA Test can offer for curious patients.

A highly illustrative video explainer on how the MSDA Test works, and what it means for your patients.

 
 
Commonly Asked Questions
What is The Octave® MSDA Test and what is in the report?

The Octave MSDA Test measures the levels of 18 proteins in your blood. The results are presented in a report shared with your doctor, which contains an overall disease activity score and four biological pathway scores reported as Low (1.0-4.0), Moderate (4.5-7.0) and High (7.5-10.0). Included in the report are also the individual 18 protein measurements with their respective scores.

The Octave MSDA Test is designed to measure the likelihood of new MS lesions seen on MRI scans. If you have a disease activity score that is High, you are more likely to have new MRI lesions than if you have a Low or Moderate score.1 These scores often change over time, so it’s important to repeat testing on an ongoing basis. Moreover, the pathway scores can provide you and your provider more insight about your disease activity.

The Octave MSDA Test must be ordered by a prescribing healthcare provider. Talk to your doctor to learn more about how they can order the test for you. Click here for an example to help guide your discussions. 

Each clinic has their own protocol for where patients can get their blood drawn. The test is intended to monitor your disease over time, so your doctor may set a schedule for how often you will receive the test in a year.

Your doctor will receive your report with the results approximately 7 days after Octave receives your sample. Your doctor may share the results with you and mutually decide on the best actions.

Octave is actively working to have all health plans to cover this test. Octave offers support to patients in understanding and managing the insurance and billing aspects related to the Octave MSDA Test. Click here to learn more.